Submission declined on 6 January 2025 by Dan arndt (talk).This submission's references do not show that the subject qualifies for a Misplaced Pages article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Misplaced Pages.The content of this submission includes material that does not meet Misplaced Pages's minimum standard for inline citations. Please cite your sources using footnotes. For instructions on how to do this, please see Referencing for beginners. Thank you.
Where to get help
You can also browse Misplaced Pages:Featured articles and Misplaced Pages:Good articles to find examples of Misplaced Pages's best writing on topics similar to your proposed article. Improving your odds of a speedy reviewTo improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources
|  |
Shlomi Raz is the leading figure in psychedelic research and is way better known for his work at Eleusis, which he co-founded to study the therapeutic potential of psychedelics. Raz's career in finance was really quite successful; this passion for psychology and an opportunity to impact large unmet medical needs pushed him to start Eleusis.
Career Background
Before Eleusis, Raz had quite a high-profile career in finance. He worked as a Managing Director at Goldman Sachs and, earlier in his career, was at JPMorgan. That background in high-stakes finance gave him the skill to navigate a complex business environment, which he brought to bear on the startup world of psychedelic medicine.
Shlomi had attended Georgetown University, where he got a Bachelor of Science in Finance, and attended New York University for his Master of Arts. These were critical academic building blocks for eventually transitioning into business, where he would learn more about leadership and finances.
Transition to Psychedelic Medicine
What really turned Raz from finance to psychedelic research was a personal interest in psychology, mixed with the profound potential of psychedelics as therapeutic agents. In 2013, he founded Eleusis, a company meant to take psychedelics into medically approved treatments. It also pointedly commits the firm to development into therapies in various indications for Alzheimer's disease, among others in mental health conditions, where it believes psychedelic drug properties stand unique, particularly because of its anti-inflammatory effects and neurogenic effects.
He would want the work being conducted at Eleusis furthers psychedelic science in every direction, enabling some desperately needed innovation in healthcare in conditions that most badly need better treatments. Eleusis leads a vanguard of psychedelic medicines targeting diseases from depression through to neurodegenerative diseases with various combinations using psilocybin and MDMA.
Business Strategy and Growth
Eleusis has been one of the cool kids under the leadership of Shlomi Raz. Headlining in 2022, it announced its plans to go public due to a merger deal with Silver Spike Acquisition Corp. II, a SPAC. That was part of the wider trend in the psychedelic sector, as some companies started to catch investor attention on a bet that attitudes to psychedelic research for medical purposes keep on improving.
Eleusis is different because it hopes to take a very scientific, data-driven perspective on psychedelic medicine. It aspires to drive the FDA and other regulatory agencies toward broad approval of psychedelic therapies across a wide array of conditions by way of clinical trials and research with the aim of showing safety and efficacy.
Vision for the Future
The vision for the future of psychedelic medicine would be to break the stigma with psychedelics, making them mainstream healthcare. He wants to bring innovative, effective treatments for people dealing with depression, anxiety, and Alzheimer's disease through his work. His passion to improve mental health through non-conventional means is what drives Eleusis's ambitious research agenda.
It's interested in the wider implications for society that psychedelic therapies can have, from shifting how we understand consciousness, mental health, and emotional well-being.
Eleusis Research Focus
Eleusis is focused on research into several areas:
Neuroinflammation probably forms one of the most interesting ways that psychedelics can act-neuroinflammation, the development of neurodegenerative pathologies such as Alzheimer's disease, a kind of keystone. In fact, there is a certain basis to believe that psychedelics enjoy a privileged role in reducing inflammatory processes of the brain and thus can point toward new avenues for therapy.
Eleusis is looking to psychedelics for treatments of depression, anxiety, and PTSD, among other mental health disorders. Indeed, those are the indications that have perhaps shown the most promise in recent studies as being spaces in which psilocybin and MDMA might be transformative.
Psychedelic-Assisted Psychotherapy: Eleusis seeks to marry psychedelic drugs with psychotherapy for a more holistic approach to curing psychiatric disorders. Already, this model developed by the organization is proving very successful in certain research studies underway by other groups, including the Multidisciplinary Association for Psychedelic Studies (MAPS).
Legacy and Impact
The impact that Shlomi Raz makes within this psychedelic space, therefore, is an ongoing thing: as emerging studies spring into the air while stigmas reduce gradually. Blending passion into therapeutic innovation along with years of experience in both business and finance, Raz tends to put himself among the frontline pioneers of these frontiers, aside from encouraging other people simply to push into an age in which psychedelics would finally find common access to contemporary pharmacopoeias.
His story underlines the trend now growing: professionals from other industries-in his case, finance-enter the psychedelic space due to a combination of personal interest and the desire to be part of something that has huge potential for societal transformation.
Raz hopes that with Eleusis, he can leave his dent in the world of medicine-something that instills hope into patients with mental health disorders and those suffering from chronic diseases.
References
https://psychedelicreview.com/person/shlomi-raz/
https://psychedelicalpha.com/news/interview-with-shlomi-raz-ceo-and-chairman-of-eleusis/
https://in.marketscreener.com/insider/SHLOMI-RAZ-A2A6KJ/
https://blossomanalysis.com/people/shlomi-raz/
Categories: